Key Takeaway: Volition has announced a webinar to introduce a groundbreaking liquid biopsy blood test aimed at early cancer detection. This method was presented at the ESMO 2023 conference, highlighting its potential impact on cancer diagnostics. The webinar will provide insights into the innovative approach and its implications for patient care.
Price reaction · baseline $23.198 (2024-02-06T17:17:00.000Z) · hit during market hours · 1 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-3.3%
Market Sentiment Analysis
POSITIVE FACTORS
Introduction of a breakthrough cancer detection method.
New liquid biopsy blood test for early cancer detection.
Presentation of data at a reputable conference (ESMO 2023).
Full Press Release Details
In this webinar, Volition introduces breakthrough data presented at ESMO 2023, regarding an entirely new liquid biopsy blood test method for the early detection of cancer.
• Share
• Tweet
• Share on Facebook
• Share
Subscribe for Volition product updates .
Or, click here for Investor Updates and press releases .
" * " indicates required fields
Frequently Asked Questions
What is the focus of the webinar?
The webinar focuses on a new liquid biopsy blood test for early cancer detection.
Where was the data for the test presented?
The data was presented at the ESMO 2023 conference.
What company is hosting the webinar?
The webinar is hosted by Volition.
What is the significance of the new method?
The new method aims to improve early detection of cancer.